OncoMatch/Clinical Trials/NCT05650580
TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
Is NCT05650580 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TR115 for non-hodgkin's lymphoma, relapsed.
Treatment: TR115 — A phase 1 dose escalation and expanded cohort study of TR115 in the treatment of adult patients with relapsed/refractory non-hodgkin's lymphoma or advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
ANC≥1.0×10^9/L (no growth factor support within 14 days of first dose); PLT≥90×10^9/L (PLT≥70×10^9/L for NHL, ≥50×10^9/L if bone marrow infiltration; no blood product transfusion within 14 days of first dose); Hb≥90g/L (Hb≥80g/L for NHL, ≥70g/L if bone marrow infiltration; no blood product transfusion within 14 days of first dose); INR or PT≤1.5×ULN, APTT≤1.5×ULN
Kidney function
Creatinine ≤1.5×ULN or Creatinine Clearance (CCr) ≥50 ml/min (Cockcroft-Gault formula)
Liver function
Total bilirubin (TBIL)≤1.5×ULN, AST and ALT≤2.5×ULN (≤5×ULN if liver involvement)
acceptable organ function: absolute neutrophil count (ANC)≥1.0×10^9/L (note: growth factor supports within 14 days of the first dose); platelet count (PLT)≥90×10^9/L （note: PLT≥70 × 10^9/L for patients with Non-Hodgkin Lymphoma (NHL) and ≥50 × 10^9/L allowed in patients with bone marrow infiltration. no blood product transfusion is allowed within 14 days of the first dose); hemoglobin (Hb) ≥90g/L (note: Hb ≥80g/L for patients with NHL and ≥70g/L in patients with bone marrow infiltration. no blood product transfusion is allowed within 14 days of the first dose); International Normalized Ratio (INR) or Prothrombin Time (PT)≤1.5×Upper limit of normal value (ULN), Activated Partial Thromboplastin Time (APTT)≤1.5×ULN ；Total bilirubin (TBIL)≤1.5×ULN, Aspartate Amino Tranferase (AST) and Alanine Transaminase (ALT)≤2.5×ULN (note: ≤ 5 × ULN if there is liver involvement); Creatinine (Cr) ≤1.5×ULN or Creatinine Clearance (CCr) ≥50 ml/min (calculated by Cockcroft-Gault formula).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify